STO · ADDV-B.ST
ADDvise Group AB (publ)
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
Loading market information…
STO · BACTI-B.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 01:47 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Bactiguard Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 25.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Bactiguard Holding AB (publ)’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of -SEK 0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bactiguard Holding AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:03 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 46.00M-8.0% vs estimate |
| Q2 2025 | Jul 15, 2025 | -SEK 0.24+7.69% vs estimate | SEK 48.00M-18.64% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | -SEK 0.14+48.15% vs estimate | SEK 59.00M+5.36% vs estimate |
|---|
| Q4 2024 | Feb 6, 2025 | -SEK 0.03+91.43% vs estimate | SEK 63.00M+14.55% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
SEK 0.47-SEK 0.01 (-2.08%)
Doxa AB’s quoted price sits in the upper half of its reported 52-week range, 14.55% below the high.
SEK 2.13-SEK 0.02 (-0.93%)
Enzymatica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.35% below the high.
SEK 31.50+SEK 0.90 (+2.94%)
FluoGuide A/S’s quoted price sits in the lower half of its reported 52-week range, 34.1% below the high.
SEK 3.20+SEK 0.40 (+14.08%)
Senzime AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
SEK 14.30+SEK 0.20 (+1.42%)
Corline Biomedical AB’s quoted price sits in the lower half of its reported 52-week range, 29.21% below the high.
SEK 0.18-SEK 0.00 (-1.85%)
Acarix AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 47.69% below the high.
SEK 9.45SEK 0.00 (0.0%)
Promimic AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 51.41% below the high.
